Healthware
hu
en
About us
Activities
Publications
Newsletter
Reference
Tender
Publications
Health-Economics
Joint model of survival time and cumulative cost, XI. Biometriai Konferencia, 2017, HUN
Data mining with graphical methods, IME, 2017, HUN
The results of the pneumococcus immunization program according to the latest surveillance data, IME, 2016, HUN
Health economic aspects of inclusion of varicella vaccination in the age-specific mandatory National Immunisation Programme, IME, 2016, HUN
Cost of severve hypoglycaemia in nine Europen countries, JME, 2016, ENG
Statistical analysis of HAQ values and resource use based on data from local patient registry in rheumatoid arthritis, ISPOR, 2014, HUN
Awareness of breast cancer and its prevention - A comparative survey among Finnish and Hungarian women, ISPOR, 2014, ENG
Cost-effectiveness of vismodegib vs standard of-care therapy in the treatment of locally advanced or symptomatic metastatic basal cell carcinoma in Hungary – An adaptation to the global cost-effectiveness model, ISPOR, 2014, ENG
The cost effectiveness of lixisenatide, a new GLP-1 receptor agonist, in the treatment of diabetes, IME, 2013, HUN
The disease burden of varicella in Hungary, ISPOR, 2012, ENG
Cost-effectiveness of Ketosteril treatment in dialysis patients. , ISPOR, 2012, ENG
Cost-effectiveness of Ketosteril treatment in stage 3-4 CKD patients, ISPOR, 2012, ENG
The cost-effectiveness analysis of Evoltra (klofarabin) in pediatric acute lymphoblastic leukemia therapy, IME, 2012, HUN
Social burden of SLE in Hungary, IME, 2012, HUN
Medical management of metastatic renal cell carcinoma, retrospective analysis of real world data settings, ISPOR, 2012, ENG
Importance of COI studies in the health care-related decision-making process through the example of rheumatiod arthitis, ISPOR, 2012, ENG
Cost-effectivness analysis of the 13-valent pneumococcal conjugate vaccine (PCV13) compared to 7-valent pneumococcal conjugate vaccine (PCV7) in Hungary, ISPOR, 2011, HUN
Measuring the indirect individual and social burden of multiple sclerosis in Hungary, IME, 2011, HUN
Quantifying the benefits of the weight gain during insulin analogue insulin therapy considering the burden of the arising complications, EGSZ, 2010, HUN
Cost-effectiveness consequences of obesity in T2DM by insulin analogue therapy, ISPOR, 2010, ENG
Pharmacoeconomic aspects of Ketosteril® treatment in stage 3-4 CKD Patients, XVth International Congress on Nutrition and Metabolism in Renal Disease, Lausanne, 2010, ENG
The health-economic approach of obesity, EGSZ, 2009, HUN
The significance of weight gain during long-acting insulin analogue therapy, EGSZ, 2009, HUN
Cost-minimisation analysis of aripiprazole (Abilify®) for the treatment of acute bipolar disorder in Hungary, MPT Congress, 2009, ENG
The economic impact of applying antiviral agents in case of pandemic, IME, 2008, HUN
Cost-effectiveness analysis of cinacalcet (Mimpara®) in Hungary, IME - META, 2008, HUN
Cost-effectiveness analysis of trastuzumab treatment of early stage breast cancer, IME, 2007, HUN
The cost-effectiveness analysis of dasatinib in imatinib resistant and intolerant patients, IME - META, 2007, HUN
Health-Economics, Methodology
Cost-effectiveness of precision oncologic decision: challenges in methodology, ISPOR, 2018, ENG
The health-economics aspects of molecular diagnostics, especially the NGS (next generation sequencing)-based molecular profile assay in oncology, META, 2018, HUN
Multi-state model applying on oncological data, IME - META, 2016, HUN
Data imputation using Bayesian methods, IME - META, 2016, HUN
Copula models and their application to examine connectedness of biomarkers, Klinikai Biostatisztikai Társaság Szemináriuma, 2015, HUN
Comparison of efficiency of different therapies on observational data by propensity score method, IME - META, 2015, HUN
The judgement of financing and cost-effectiveness of infant nutrition, IME - META, 2015, HUN
Methodological difficulties of compliance analysis based on Real-World Data, ISPOR, 2015, ENG
New statistical methods: copula models in health economics, IME - META, 2014, HUN
The possible spread of Telemedicine Services in the near future, IME, 2011, HUN
Defining social discount rate in Hungary using the Ramsey-formula, Diszkontráta Munkacsoport, 2010, HUN
Possibilities of applying patient flow modelling, IME, 2009, HUN
Healthcare financing
No more drivers – The seven years of generic substitution. PirulaTrend Magazine, 2019/3, HUN
Market access növekvő kihívásai, META, 2022, HUN
A gyártói befizetési kötelezettség emelésének hatása a gyógyszerkassza egyenlegére, META, 2022, HUN
The main trends of ongoing drug developments, META, 2018, HUN
Analytical opportunities of the itemized patient turnover report (B300), IME, 2017, HUN
Is it worth appliyng data more frequent than monthly to forecast drug turnover?, IME - META, 2015, HUN
Redel Study: Differences in reimbursement delays In CEE Countries, ISPOR, 2014, ENG
Evaluation of the social welfare part of the Hungarian drug provision system, ISPOR, 2014, ENG
Decreasing drug prices - Descending patient burden?, VG, 2012, HUN
How much the government spends on medicine? - Difficulties of defining the public health expenditures for medicines, IME, 2012, HUN
Harmonization of innovations and reimbursement principles in medicine supply, IME, 2011, HUN
Future of financer’s risk management in drug reimbursement, IME, 2011, HUN
The benefit of a new cash flow model in healthcare financing, IME - META, 2011, HUN
International assessment of expenditure reducing drug price regulatory tools, IME, 2011, HUN
The importance of developing partnerships in healthcare financing, IME, 2010, HUN
Financial opportunities of working capital raising in health care system, IME, 2010, HUN
The increasing role and burden of biological therapies, VG, 2009, HUN
Issues of the optimization of domestic pharmaceutical companies’ contribution , IME, 2008, HUN
The results of new social welfare provision, VG, 2008, HUN
The governmental actions of 2004: goals and impact on drug budget, IME, 2007, HUN
Reference-price adjusted reimbursement: tool and opportunity, IME, 2007, HUN
Regulation of prescription practice: cardinal issues, OTSZ, 2007, HUN
GPs who prescribe the more expensive drug would be fined, VG, 2007, HUN
'Two-level' drug price – reimbursement is expected, VG, 2007, HUN
Adjustments in drug budget, VG, 2007, HUN
Immediate reform needed, VG, 2006, HUN
Agreement, gradualism, predictability, VG, 2006, HUN
Outcome measurement
Risk of exacerbation and mortality in asthma: a 10-year retrospective financial database analysis of the Hungarian Health Insurance Fund, BMJ, 2024, ENG
Nationwide Study of Real-World Treatment Patterns and Clinical Outcomes in Patients with Metastatic Urothelial Carcinoma in Hungary, Advances in Therapy, 2023, ENG
Qualitative and quantitative comparison of two semi‑manual retinal vascular density analyzing methods on optical coherence tomography angiography images of healthy individuals, Scientifc Reports, 2023, ENG
Deficiencies in the Recognition and Reporting of Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus; A Hungarian Nationwide Analysis, IJPH, 2023, ENG
Severe exacerbations and mortality in COPD patients: A retrospective analysis of the database of the Hungarian National Health Insurance Fund, Pulmonology, 2023, ENG
Comparative effectiveness of second generation long-acting injectable antipsychotics based on nationwide database research in Hungary: an update, Oxford Academic, 2022, ENG
Real-world treatment patterns and clinical outcomes in patients with metastatic urothelial carcinoma (mUC): results of a nationwide, longitudinal, retrospective study in Hungary, ESMO Congress, 2022, ENG
Clinical characteristics of treatment-resistant depression in adults in Hungary: Real-world evidence from a 7-year-long retrospective data analysis, PLOS, 2021, ENG
Does inflammatory bowel disease have different characteristics according to stage of adolescence?, SAGE, 2021, ENG
Comparative effectiveness of second generation long-acting injectable antipsychotics based on nationwide database research in Hungary, PLOS, 2019, ENG
Cost-effectiveness analysis of basal insulin-supported oral therapy using human or analogue insulin type 2 diabetes in hungary, ISPOR, 2018, ENG
Categorising patients with rheumatoid arthritis using trajectories of disease activity score in hungary, ISPOR, 2018, ENG
Data science and an analytical framwork of high risk diseases and mortality in Hungary – Breast cancer, IME, 2018, HUN
Data science and an analytical framwork of high risk diseases and mortality in Hungary, IME, 2018, HUN
Analysis of regional patterns in the epidemiology and survival of patients with prostate cancer using nationwide real-world data, META, 2018, HUN
Long term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary, 2017, ENG
Mortality and the relationship of somatic comorbidities to mortality in schizophrenia. A nationwide matched-cohort study, European Psychiatry, 2017, ENG
Old and new oral anticoagulants in the management of atrial fibrillation, Orvosi Hetilap, 2017, HUN
Multifactor analysis for effectiveness based evaluation/assessment of high value therapies, IME, 2017, HUN
Methods for process analysis and assessment in development of health care/reimbursment protocols, IME, 2017, HUN
Oppurtunities and challenges of the performance-based financing in drug reimbursement, IME, 2017, HUN
Comparison study based on simulation of patient pathways using multi-state models in oncology, ISPOR, 2016, ENG
Childhood cancer: analysis of overall survival and other relevant events, IME - META, 2016, HUN
The burden of adult Pneumococcal disease in 50+ population in Hungary, IME, 2016, HUN
Effectiveness of biological therapies applied in early stage on Hungarian patients with rheumatoid arthritis disease, IME - META, 2015, HUN
The burden of adult pneumococcal disease in 50+ population in Hungary, ISPOR, 2015, ENG
Changes in the mortality rate during the last decade in the fields of oncology in Hungary, ISPOR, 2015, ENG
Comparative statistical analysis of osteoporosis treatment based on Hungarian claims data and interpretation of the results in respect to cost-effectiveness, Osteoporos Int, 2014, ENG
Association of treatment compliance with fracture-related hospitalisations and their associated costs among Hungarian women with postmenopausal osteoporosis (PMO), WCO-IOF-ESCEO, 2014, ENG
Analysis of reimbursed biological therapy use in the treatment of plaque psoriasis in Hungary based on the National Health Insurance Fund Administration’s data, HTSZ, 2014, HUN
Modeling dependence between disability status and health service costs of patients with rheumatoid arthritis in Hungary, ISPOR, 2014, ENG
Burden of disease analysis of ankylosing spondylitis in Hungary, ISPOR, 2014, ENG
Burden of disease analysis of psoriatic arthritis, ISPOR, 2014, ENG
Comparative effectiveness of depot and oral second generation antipsychotic drugs in schizophrenia: A nationwide study in Hungary, EURONEURO, 2013, ENG
Analysis of the epidemiology and therapeutic practise of heart failure insufficiency from the Hungarian Health Insurance Fund Administration database, IME, 2012, HUN
The epidemiology and therapeutic practise of heart failure insufficiency in Hungary in the beginning of 21st-century, Cardiologia Hungarica, 2012, HUN
Impact of compliance and other factors on fracture risk for osteoporosis in postmenopausal women in Hungary, ISPOR, 2012, ENG
A retrospective cohort study of persistence & compliance to treatment for osteoporosis in postmenopausal women in Hungary, ISPOR, 2012, ENG
A retrospective cohort study of persistence & compliance to treatment for osteoporotic men in Hungary, ISPOR, 2012, ENG
Effectiveness of osteoporosis treatment in Hungary, LAM-KID, 2012, HUN
Adherence among postmenopausal osteoporotic women in Hungary, LAM-KID, 2012, HUN
The experience of 'Changing Diabetes Baromete' in Hungary, IME, 2011, HUN
Health Insurance
Modeling of distribution and expected value of expenses after certain events with Cox’s proportional hazard model, IME, 2012, HUN
Bankruptcy risk and brokerage model of the insurance packages , IME, 2012, HUN
Criteria system of market assessment for strategic decisions, IME, 2010, HUN
Estimating the healthcare costs for creating the capitation fee based on demographic characteristics in Hungary, IME, 2008, HUN
Possibilities of fee calculation of insurance products in private insurance, IME, 2008, HUN
Biztosítási termékek díjkalkulációjának lehetőségei a magánfinanszírozásban, 2008.
Healthcare reform: raising capital or withdrawal of funds?, IME, 2008, HUN
Modelling of the health insurance systems in healthcare financing, IME, 2008, HUN
Meta-analysis
Comparing the effect of once-per-day-applied analogue basal insulins among type 2 diabetes patients, OTSZ, 2009, HUN
Contact us!
I accept
GDPR Enchantments
Send
Contact
1093 Budapest, Közraktár utca 32. RiverPark Irodák, VII. emelet
+36 1 324 2050
+36 1 324 2051
iroda@healthware.hu